Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard

Project description

Validating an innovative biomedical device for the management of medical waste

Biological fluids constitute a threat to the community, the health workforce and the natural environment. It is estimated that the European healthcare industry spends EUR 10 billion annually on the disposal of infectious/hazardous medical waste, with its global production reaching approximately 7 000 tonnes daily. The EU-funded ABT project aims at validating the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT), an innovative biomedical device based on the Axivirium BIOACTIVE® molecules, able to improve the efficiency and reduce the cost of biomedical fluids disposal. The implementation of the new technology will significantly reduce the biological risks associated with medical waste.

Objective

The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

ENPROJECT MEDICALI SRL
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
VIALE CARLO FAINA 30
06055 MARSCIANO
Italy

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Centro (IT) Umbria Perugia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0